Success in the development of the medicinal product Dapagliflozinum 10 mg

We are pleased to announce that the newly developed medicinal product Dapagliflozinum, 10 mg, coated tablets, has successfully passed bioequivalence testing.

The project is co-financed from the state budget by the Medical Research Agency as part of project No. 2022/ABM/04/00021 – “Development and advancement of a medicinal product with the active substance dapagliflozin – a generic drug for type 2 diabetes”.

The results obtained represent an important stage in the product development process, bringing us closer to the launch of an effective and safe therapy for patients with type 2 diabetes.

Thanks to the knowledge and commitment of our team of experts, we are consistently developing therapies that respond to the real needs of patients.

At Polfa, we believe that development in pharmacy has the real power to change lives. 💙